Drugs · Brain health technique
Anti-Amyloid Monoclonal Antibodies
Evidence grade: Context Dependent
FDA-approved biologic drugs that target beta-amyloid plaques to slow Alzheimer’s progression, including lecanemab (Leqembi®), donanemab (Kisunla™). These antibodies enhance immune-mediated clearance of amyloid from the brain, aiming to preserve cognitive function in early-stage disease.
- Practice
- Drugs
- Principle
- Treatment
- Tactic
- Neuroprotective & Disease-modifying Therapies
- Evidence grade
- Context Dependent
- Strength of evidence
- Medium
- Effort
- Medium
- Time commitment
- High
How to practice Anti-Amyloid Monoclonal Antibodies
Indicated for early Alzheimer’s confirmed by amyloid PET and cognitive testing. Administered via IV infusion every 2–4 weeks in specialized centers. Requires MRI monitoring for ARIA and APOE genotyping. Benefits are disease-modifying but partial; not for late-stage disease or asymptomatic use. Best outcomes occur with early diagnosis and concurrent vascular/metabolic optimization.
The evidence behind Anti-Amyloid Monoclonal Antibodies
Large phase 3 trials (e.g., CLARITY-AD, TRAILBLAZER-ALZ 2) show roughly 25–35% slowing of cognitive decline in MCI and early Alzheimer’s. Mechanism: antibodies bind aggregated amyloid, promoting microglial clearance and reducing neuroinflammation. Evidence strong for amyloid reduction and modest for clinical benefit. Main risk: amyloid-related imaging abnormalities (ARIA) causing swelling or microbleeds, particularly in APOE-ε4 carriers.
More Drugs techniques
Take control of your brain health
BetterBrain gives you a personalized protocol of techniques like these, backed by science and tailored to you.